Anti-TNF-α therapy in ankylosing spondylitis
- 1 July 2004
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 5 (7) , 1497-1507
- https://doi.org/10.1517/14656566.5.7.1497
Abstract
Ankylosing spondylitis (AS) is a frequent disease leading to functional impairment and socioeconomic burden. Anti-TNF-α therapy has brought new perspectives in this condition. Two agents are currently used in the treatment of AS and spondyloarthropathies – infliximab (a chimeric monoclonal antibody) and etanercept (a soluble p75 TNF-receptor). Open-label studies have shown the feasibility and efficacy of these drugs. Controlled studies have confirmed the latter, at least in the short-term (1 year). Improvement in several clinical parameters, function, quality of life, biological parameters and magentic resonance imaging acute inflammation, have been observed. Due to these favourable results, anti-TNF have been approved for the treatment of AS. However, there are some safety concerns, essentially involving infection. Consensus guidelines for the use of anti-TNF in AS are available and assessment is based on validated tools. However, some questions still remain unanswered, such as the long-term efficacy and...Keywords
This publication has 39 references indexed in Scilit:
- A six‐month randomized, controlled, double‐blind, dose‐response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitisArthritis & Rheumatism, 2002
- Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitisArthritis & Rheumatism, 2001
- Employment, work disability, and work days lost in patients with ankylosing spondylitis: a cross sectional study of Dutch patientsAnnals of the Rheumatic Diseases, 2001
- Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptomsThe Lancet, 2000
- Successful treatment of active ankylosing spondylitis with the anti–tumor necrosis factor α monoclonal antibody infliximabArthritis & Rheumatism, 2000
- Prevalence of spondylarthropathies in HLA-B27 positive and negative blood donorsArthritis & Rheumatism, 1998
- Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitisArthritis & Rheumatism, 1995
- SERUM CYTOKINES (IL-6, TNF-α, IL-1β AND IFN-γ) IN ANKYLOSING SPONDYLITIS: A CLOSE CORRELATION BETWEEN SERUM IL-6 AND DISEASE ACTIVITY AND SEVERITYRheumatology, 1994
- Prevalence of ankylosing spondylitis in males and females in a young middle-aged population of Tromsø, northern Norway.Annals of the Rheumatic Diseases, 1985
- Evaluation of Diagnostic Criteria for Ankylosing SpondylitisArthritis & Rheumatism, 1984